| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Federal Circuit Denies Pfizer's Petition For Rehearing In Norvasc Case
Posted on 05/22/2007 05:18:47 | Link | Post Comment
by Aaron F. Barkoff
Orange Book Blog
Reuters reported this afternoon that the Federal Circuit has denied Pfizer's petition for rehearing and rehearing en banc of Pfizer vs. Apotex, in which the court invalidated claims 1-3 of Pfizer's U.S. Patent No. 4,879,303. The '303 patent covers amlodipine besylate, the active ingredient in Norvasc.
According to the Reuters article, three Federal Circuit judges (out of twelve) dissented from the decision not to rehear the case. The court has not yet listed the decision on its disposition sheet, nor has it published any opinions on the decision.
The most immediate beneficiary of today's decision may be Apotex. The FDA previously announced that it would grant final approval to Apotex's ANDA for generic Norvasc when the Federal Circuit's mandate issues. Now that the Federal Circuit has denied Pfizer's petition for rehearing, it is expected to issue the mandate within seven calendar days.
As we've previously reported, Mylan filed suit against the FDA to stop FDA from approving any other generic versions of Norvasc. Mylan will likely file a motion with the D.C. Circuit to prevent FDA from approving Apotex's ANDA, pending its appeal.
Source: OrangeBookBlog.com
RELATED READING:
- District Court Denies All Challenges to FDA Decision on Norvasc Exclusivity
- Mylan Launches Generic Norvasc; Pfizer Counters with Own Generic
- Pfizer Wins Another Round in Norvasc Case as Synthon's Patents Are Found Unenforceable
______________________
Orange Book Blog
Reuters reported this afternoon that the Federal Circuit has denied Pfizer's petition for rehearing and rehearing en banc of Pfizer vs. Apotex, in which the court invalidated claims 1-3 of Pfizer's U.S. Patent No. 4,879,303. The '303 patent covers amlodipine besylate, the active ingredient in Norvasc.
According to the Reuters article, three Federal Circuit judges (out of twelve) dissented from the decision not to rehear the case. The court has not yet listed the decision on its disposition sheet, nor has it published any opinions on the decision.
The most immediate beneficiary of today's decision may be Apotex. The FDA previously announced that it would grant final approval to Apotex's ANDA for generic Norvasc when the Federal Circuit's mandate issues. Now that the Federal Circuit has denied Pfizer's petition for rehearing, it is expected to issue the mandate within seven calendar days.
As we've previously reported, Mylan filed suit against the FDA to stop FDA from approving any other generic versions of Norvasc. Mylan will likely file a motion with the D.C. Circuit to prevent FDA from approving Apotex's ANDA, pending its appeal.
Source: OrangeBookBlog.com
RELATED READING:
- District Court Denies All Challenges to FDA Decision on Norvasc Exclusivity
- Mylan Launches Generic Norvasc; Pfizer Counters with Own Generic
- Pfizer Wins Another Round in Norvasc Case as Synthon's Patents Are Found Unenforceable
______________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- Newmark's Door
- The Family CEO
- Ludwig von Mises Institute
- Credit Bloggers
- Wishing Wealth
- Financial Skeptic
Examples
Boucher On The Big Picture - Thu Aug 14, 2008 04:54PM
Watch Interest Rates Next For Clue as to When Downside R [read more]
Watch Interest Rates Next For Clue as to When Downside R [read more]
Morpheus Trading - Thu Aug 14, 2008 07:54AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
Editorial Spotlight - Fri Aug 15, 2008 10:33AM
They say the most dangerous enemy is the one you don’ [read more]
They say the most dangerous enemy is the one you don’ [read more]
<< My Home | TheMoneyBlogs Home